

IBC Meeting Minutes
5/14/2026 12:05 PM
CMRI Conference Room 31 & Teams

MEETING TIME RECORDS**Meeting start time:** 12:05**Meeting end time:** 13:34**VOTING MEMBER ATTENDANCE**

Name of IBC Member	Committee Role	Late Arrival Time	Early Departure Time
Daniel Heruth	Chair, Animal Expert, Lab Rep		
Todd Bradley	Co-Chair, Lab Rep		
Paul Ramlow	BSO, Animal Expert, Lab Rep		
Vivekanand Yadav	Alternate Lab Rep (Tarak)		
James Slaughter	Local Non-Affiliated		
Judy Dilts	Local Non-Affiliated		
Tamie Crutchfield	Occupational Health	12:10	

VOTING MEMBERS ABSENT

Tarak Srivastava	Lab Rep		
------------------	---------	--	--

NON-VOTING MEMBERS PRESENT

Foster St. Claire	AV & Ex-Officio		
-------------------	-----------------	--	--

ADMINISTRATIVE STAFF

Saskia Miller	Director of the ORI		
Lizzie Short	Associate Director of the IBC		
Daniel Crabtree	Sr. IBC Manager		
Kelleigh Pearson	Administrative Project Coordinator		

QUORUM INFORMATION**Number of SAFETY members on the roster:** 7**GUEST NAMES**

No guests at this meeting.

Conflict of Interest (COI): Chair reminded the Committee to declare any COI.

Previous Meeting minutes approved: Yes

A motion to approve was made and seconded. The motion passed with 5 votes in favor, 2 absent.

BIOSAFETY COMMITTEE UPDATES

1. Biological Safety Officer (BSO) Updates

The Chair provided an update on behalf of the BSO due to the BSO's absence while responding to [REDACTED] laboratory incident. [REDACTED]

[REDACTED] The Chair noted that the BSO will present the incident report and associated remediation at the June 11, 2026 IBC meeting.

The Chair reported a separate laboratory event [REDACTED]

[REDACTED] The BSO has met with the Principal Investigator and research staff to review the incident and discuss corrective actions. Additional education and follow-up are ongoing. Details will be reported to the IBC once the incident report is finalized.

2. Office of Research Integrity (ORI) Updates

The Associate Director provided an overview of the upcoming AAALAC reaccreditation process.

It was also noted that, due to a new institutional policy, meetings will now begin five minutes after the hour.

REVIEW OF SUBMISSIONS

[REDACTED]		[REDACTED]	
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[illegible]

De Novo Review**5. Review of IBC00116**

Title:	GMC Repository and NGS
Investigator:	Emily Farrow
Submission ID	IBC00116
Agents:	• Semen • Cerebrospinal Fluid • Synovial Fluid • Amniotic Fluid • Saliva • Mucus Membrane Tissue • Cardiovascular Tissue • Digestive Tissue • Endocrine Tissue • Integumentary • Muscular Tissue • Nervous Tissue • Reproductive Tissue • Respiratory Tissue • Skeletal Tissue • Human Derived Blood and Blood Types • HEK-293T • Mouse Tissue • Avian Tissue • NA12878
Agent Characteristics:	Biological Agent Sources: • Consented patients/adults • Investigators using the CPGM as a core facility • Samples are obtained from clinically indicated procedures or from research consented patients. • ATCC • Coriell Institute Recombinant Nucleic Acid Work: Polymerase chain reagent sequencing is a component of library preparation

	for sequencing using oligos that are purchased from vendors such as IDT Dna or Illumina. This protocol is to cover core library preparation for short read sequencing (illumina) and long read sequencing (PacBio) using kits purchased from the vendors. Vectors: This protocol is to cover standard kitted library prep- no cloning, expression, or modification of genes, and no host-vector systems or regulatory elements are employed.
Agent Containment:	Biological Containment Levels: • Semen: BSL-2 • Mouse Tissue: BSL-1 • Muscular Tissue: BSL-2 • Avian Tissue: BSL-1 • Reproductive Tissue: BSL-2 • Nervous Tissue: BSL-2 • Cerebrospinal Fluid: BSL-2 • Respiratory Tissue: BSL-2 • Synovial Fluid: BSL-2 • Skeletal Tissue: BSL-2 • Saliva: BSL-2 • Human Derived Blood and Blood Types: BSL-2 • Mucus Membrane Tissue: BSL-2 • Endocrine Tissue: BSL-2 • Amniotic Fluid: BSL-2 • Cardiovascular Tissue: BSL-2 • Digestive Tissue: BSL-2 • Integumentary: BSL-2 • HEK-293T: BSL-2 • NA12878: BSL-2
Applicable NIH Guidelines:	• Section III-F • Section III-F-1

Determination: Modifications Required**Last day of continuing review period:** N/A**Required modifications:**

- Update the name of the core facility throughout the protocol to reflect the recent name change and ensure consistent use of “GMC.”
- Revise biosafety measures to address the risk of exposure to bloodborne pathogens by adding surgical mask use to protect mucous membranes due to aerosol generation.
- Remove the word “personal” from the relevant exposure-response header and revise the language to focus on actions taken “in the event of exposure.”
- Provide agent-specific tissue handling details, including appropriate units (mg for solid tissues and volumes for liquid specimens such as CSF), rather than duplicative descriptions across agents.

- Revise responses related to avian tissue to reflect that IRB oversight does not apply and correct inaccurate references to IRB-related sources.
- Expand the justification for why DURC is not applicable, clarifying that gene products will not be manipulated to enhance pathogenicity.
- Update the r/sNA section (Question 2) to include details on targeted genes or indicate whether whole human genome amplification is being performed.
- Remove or update references to Crown Center, as the Genome Center is no longer located at that site.

Comments:

The Chair provided an overview of the protocol.

A member requested that the name of the core facility be updated throughout the protocol to reflect a recent name change. The document should be revised to use “GMC” consistently.

A member noted that the primary risk to laboratory personnel is exposure to bloodborne pathogens, either through aerosol generation or sharps (e.g., pipette tips). Given the aerosol risk, the committee recommended that staff also wear surgical masks to protect mucous membranes.

A member requested that the word “personal” be removed from the relevant header and that the language focus on “in the event of exposure.” It was also noted that the IBC Researcher User Guide will be updated to reflect this change.

Regarding tissue amounts and details, the committee noted that the descriptions currently appear to be duplicated across agents and lack specificity. The protocol should be revised to provide agent-specific details, including appropriate units (e.g., mg for solid tissues and volume for liquid specimens such as CSF).

For avian tissue, the PI indicated IRB review; however, the committee clarified that this would not fall under IRB oversight and that the response should be revised. The referenced IRB-related source is also inaccurate and should be corrected.

The committee requested a more detailed justification for why DURC is not applicable, including clarification that gene products will not be manipulated to enhance pathogenicity.

In the r/sNA section (Question 2), additional detail is required describing the genes targeted or whether whole human genome amplification is being performed.

The committee noted that references to Crown Center must be updated, as the Genome Center is no longer located at that site.

A motion to require modifications to secure approval was made and seconded. The motion passed (6 in favor, 0 opposed, 1 absent).

Supporting documents:

None

Votes:

For: 6
Against: 0
Recused: 0
Absent: 1
Abstained: 0

REVIEW OF OTHER AGENDA ITEMS

6. Review of IBC Member Evaluation Summary:

Description:	The Associate Director will review the IBC Member Evaluation Summary with the Committee.
Notes:	The Associate Director gave an overview of the IBC Member evaluations. No questions or concerns from the Committee.

ACKNOWLEDGMENTS SECTION

The following items were approved outside of a convened IBC meeting. The Committee reviewed and acknowledged the following items during this meeting.

ID	Name	State	Specialist	Agenda Type
SAMEND202600015	Amendment for IBC00080	Approved	Elizabeth Short	Admin Approval
SAMEND202600016	Amendment for IBC00111	Approved	Daniel Crabtree	Admin Approval
SAMEND202600017	Amendment for IBC00105	Approved	Daniel Crabtree	Admin Approval
SAMEND202600018	Amendment for IBC00100 remove personnel	Approved	Elizabeth Short	Admin Approval
SAMEND202600019	Amendment for IBC00091	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202600003	Amendment/CR for IBC00077	Approved	Elizabeth Short	Admin Approval
SAMENDCR202600004	Amendment/CR for IBC00097	Approved	Daniel Crabtree	Admin Approval